Side-by-side · Research reference
DSIPvsPT-141
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft8/36 cited
BFDA-ApprovedReviewed13/41 cited
DSIP
Sleep modulator · Anti-stress
SQ · Pre-sleep · Daily during cycle
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
01Mechanism of Action
Parameter
DSIP
PT-141
Primary target
Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Pathway
Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Downstream effect
Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Feedback intact?
—
—
Origin
Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Antibody development
—
—
02Dosage Protocols
Parameter
DSIP
PT-141
Standard dose
100–200 mcg SQ pre-sleepSchneider 1986
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
Frequency
Once daily, pre-sleep
PRN, max 8 doses / month
Lower / starter dose
50 mcg pre-sleep
1 mg (off-label)
Evidence basis
Human-mechanistic + early clinicalSchneider 1986
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Duration
8–12 weeks per cycle
PRN; reassess if no benefit after 8 doses
Reconstitution
Bacteriostatic water
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Timing
30–60 min pre-sleep
≥45 min before sexual activity
04Side Effects & Safety
Parameter
DSIP
PT-141
Injection site reaction
Mild irritation
Erythema, mild pain
Drowsiness
Expected effect (intentional)
—
Vivid dreams
Anecdotally reported
—
Long-term safety
Limited modern RCT data
—
Pregnancy / OB
Avoid
Contraindicated
Flushing
—
Common, transient
Headache
—
Common
Hyperpigmentation (focal)
—
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
Hypertension (transient)
—
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
Cardiovascular disease
—
Use caution; transient BP rise
Absolute Contraindications
DSIP
- ·Pregnancy / breastfeeding
- ·Concurrent CNS-depressant therapy without supervision
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Relative Contraindications
DSIP
- ·Severe sleep apnoea (untreated)
- ·Concurrent benzodiazepine / opioid use
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
05Administration Protocol
Parameter
DSIP
PT-141
1. Reconstitution
Add 1–2 mL bacteriostatic water to vial.
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
2. Injection site
SQ — abdomen. Rotate sites.
SQ — abdomen or thigh.
3. Timing
30–60 min pre-sleep.
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
5. Needle
29–31G insulin syringe.
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.